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Comprehensive Cancer Center, Los Angeles, CA 90033,Introduction: Type 2 diabetes mellitus (T2DM) affects huge populations in India and abroad. Genetic
polymorphisms (SNPs) in scavenger receptors such as CD36 have been implicated in the pathogenesis
of diabetic atherosclerosis and cardiovascular diseases. Since CD36 gene expression contributes to
T2DM, we proposed to study the association of two of its polymorphisms.
Methods: A population of 400 subjects from North India was analyzed according to clinical parameters.
Out of them 150 controls and 250 T2DM patients were genotyped for two SNPs namely rs1761667
(G > A) and rs1527483 (C > T) in the CD36 gene using polymerase chain reaction and restriction fragment
length polymorphism (PCR–RFLP) followed by statistical analysis.
Results and discussion: No association of rs1527483 (C > T) SNP was observed in T2DM patients. The GA
genotype was prevalent in 76.0% diabetic population and a highly signiﬁcant genotypic association of
rs1761667 (G > A) SNP in CD36 gene was observed in them (P = <0.001; OR 3.173; CI 1.098–9.174). Sam-
ple characteristics showed a highly signiﬁcant association with lipid proﬁle (P = <0.001). The ‘GA’ geno-
type in combination with CC genotype showed a signiﬁcant association with TC (P = 0.020), LDL
(P = 0.005) and VLDL (P = 0.029). In addition, the haplotype analysis CC/GA (/+) and CT/GA (/+) showed
a strong association with TC and LDL (P < 0.05). The presence of 31118 A* allele in haplotypes showed
strong association with T2DM (P = <0.005).
Conclusion: Out of the two CD36 gene polymorphisms tested, rs1761667 SNP is signiﬁcantly associated
with T2DM with the GA heterozygous genotype showing highest frequency among the T2DM patients.
 2010 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.1. Introduction insulin resistance in liver and skeletal muscle, the organs responsi-Type 2 diabetes mellitus (T2DM) is a part of metabolic syn-
drome (MetS) which is affected both by environmental, as well
as genetic factors. Many studies suggest that net lipid accumula-
tion, caused by an imbalance between fatty acid delivery/synthesis
and fatty acid oxidation, results in the activation of a serine kinase
cascade [1,2]. This in turn, inhibits insulin signaling, resulting inellitus. Published by Elsevier Ltd.
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Oble for majority of glucose disposal. CD36 (FAT, SCARB3, GP88, gly-
coprotein IV (gpIV) and glycoprotein IIIb (gpIIIb)) is a broadly
expressed 88 kDa membrane transporter glycoprotein that acts
as a facilitator of fatty acid (FA) uptake, a signaling molecule and
a receptor for a wide range of ligands [3]. In addition to FAs,
CD36 binds to native lipoproteins and functions in the uptake of
cholesteryl esters, facilitates the uptake of oxidized low/high-den-
sity lipoproteins and cholesterol [4–8]. As a result of its many li-
gands and functions, CD36 could impact a variety of conditions
linked with the metabolic syndrome, including diabetes, insulin
resistance, inﬂammation and atherosclerosis [9,10].
The CD36 gene spans 36 Kb (7q11.2–7q21.11) and is comprised
of 15 alternatively spliced exons that are differentially regulated by
several upstream promoters [11,12]; CD36 plays an important role
in lipid metabolism and its gene polymorphisms are related to
hypertension [13], MetS and high-density lipoprotein cholesterol
(HDL-C) [14]. Since there have been very few studies on the
association of genetic variants in the CD36 gene with T2DM
[15–17], we proposed to investigate two probable CD36 genepen access under CC BY-NC-ND license.
Table 1
Primer sequences, PCR conditions, amplicon sizes, restriction enzymes with product sizes of SNPs in CD36 gene.
SNP Primer sequence Annealing temp. (C) Product size (bp) Restriction enzyme/allele sizes
SNP (C > T) rs1527483 F: 50-CGCTACAACAATTTTATAGATTTTGAC-30 55 252 Taq I
CC 160,70,22
25,444 intron 11 R: 50-TGAAATAAAAATAATCTTGTCGATGA-30 CT 230,160,70,22
TT 230,22
SNP (G > A) rs1761667 F: 50-CAAAATCACAATCTATTCAAGACCA-30 56 190 Hha I
GG 138, 52
31118 Promoter 50 region of exon 1A R: 50-TTTTGGGAGAAATTCTGAAGAG-30 GA 190, 138, 52
AA 190
180 M. Banerjee et al. / International Journal of Diabetes Mellitus 2 (2010) 179–183polymorphisms that might have an important role to play in T2DM
and related complications. This is perhaps the ﬁrst report of CD36
gene polymorphism study in T2DM patients from Northern India.2. Material and methods
2.1. Patients and clinical evaluation
Type 2 diabetic patients, 22–77 years of age (n = 250) were en-
rolled from the outpatient Diabetes Clinic of Chhatrapati Shahuji
Maharaj Medical University (CSMMU), Lucknow under the supervi-
sion of expert clinicians. Age/sex-matched normal healthy controls
(n = 150) were screened from healthy staff members of both Uni-
versities. The study was approved by the Medical Ethical Commit-
tee of CSMMU and a written informed consent was taken from all
subjects enrolled for the study. Controls showing a normal oral
glucose tolerance test were included in the study, whereas those
having a history of coronary artery disease or other metabolic dis-
orders were excluded. Subjects with fasting glucose concentrations
P126 mg/dl or 2-h glucose concentrationsP200 mg/dl after a 75-
g oral glucose tolerance test were categorized in the diabetes
group. Medical records of these patients were reviewed to ascer-
tain diabetes-associated complications. A self-administered ques-
tionnaire was used to record the clinical history of diabetes,
associated complications such as hypertension as well as family
history. All patients were on oral hypoglycemic agents to maintain
a normal glucose level in their blood.
Estimations of plasma glucose (mg/dl), serum insulin (mg/dl)
and lipid proﬁle (total serum cholesterol (TC), high-density lipo-
protein cholesterol (HDL-C) and serum triglycerides) were done
using commercially available Ecoline kits from Merck by double
beam spectrophotometer at 550 nm (TGL-C), 510 nm (serum creat-
inine), 500 nm (total cholesterol) and 560 nm (HDL-C) [18]. Height,
weight and waist circumference were measured to calculate body
mass index (BMI) and waist hip ratio (WHR). Systolic and diastolic
blood pressures were measured in the sitting position with an
appropriately sized cuff after a 5 min rest. Clinical details of pa-
tients and controls were recorded.
2.2. DNA extraction and CD36 gene polymorphisms
Five milliliter of blood sample was taken in EDTA vials from
both the groups. Genomic DNA was extracted from peripheral
blood leucocytes using the standard salting out method [19].
Two CD36 single nucleotide polymorphisms (SNPs) viz. G > A
(rs1761667) in the 31118 promoter region of exon 1A and C > T
(rs1527483) in intron 11 were genotyped in 150 controls and
250 T2DM patients using polymerase chain reaction and restriction
fragment length polymorphism (PCR–RFLP) method. Primers for
the SNPs were designed and restriction enzymes (REs) were iden-
tiﬁed using the Primer 3 and NEB cutter softwares respectively. De-
tails including the location of SNPs in the CD36 gene, primer
sequences and REs with product sizes are presented in Table 1.
PCR was performed in a 25 ll reaction mixture containing genomicDNA (100–150 ng), 10 pmol of each primer, 200 lM dNTPs, and
05 U of Taq DNA polymerase (MBI-Fermentas, USA) in a gradient
Master Cycler (Eppendorf, USA). The PCR products were digested
with the respective restriction enzymes, resolved on 2% agarose
and 12% polyacrylamide gels.
2.3. Statistical analysis
Allele frequencies, genotype frequencies and carriage rates of
the alleles in all the groups were compared using 2  2 contingency
table by Fisher’s exact test. The Hardy–Weinberg equilibrium at
individual loci was assessed by chi-square (v2) statistics using SPSS
(v 15.0). Allele frequency was calculated as the number of occur-
rences of the test allele in the population divided by the total
number of alleles. Carriage rate was calculated as the number of
individuals carrying at least one copy of test allele divided by the to-
tal number of individuals. Association of various clinical parameters
with different CD36 (SNPs C/T and G/A) genotypes in T2DMpatients
and controls was calculated by 2  2 paired t-test. Differences were
considered statistically signiﬁcant for P < 0.05. The strength of asso-
ciation of SNP-SNP combinations was determined by Odds ratio
(OR) at 95% conﬁdence interval (CI) using Logistic Regression Anal-
ysis (SPSS). Multivariate Logistic regression analysis was used to
examine the association of biochemical parameters with different
haplotypes of the two SNPs. Data were presented as mean ± SD.
3. Results
3.1. Characteristics of the sample population
Out of the total number of subjects (n = 400) included in the
study, 150 were healthy controls with an average age of
47.07 ± 6.01 years, their fasting and post prandial glucose levels
were 109.69 ± 51.96 and 143.69 ± 21.46 mg/dl, respectively. The
average age of the patients (n = 250) was 48.39 ± 9.91 years, their
fasting and postprandial glucose levels were 166.14 ± 65.76 and
266.40 ± 88.45 mg/dl, respectively. The patients average systolic
BP was slightly elevated (135.22 ± 19.35 mm Hg) and the mean
diastolic pressure was almost normal (84.27 ± 10.77 mm Hg). Total
cholesterol (225.83 ± 34.83 mm/dl) and LDL-C (158.00 ± 37.04 mm
Hg) levels were slightly raised and HDL-C was low (43.47 ±
5.26 mm Hg) in patients. Therefore, the lipid proﬁle in patients
showed a signiﬁcant difference when compared to control subjects
(P < 0.001). However, no signiﬁcant difference was observed in
BMI, WHR and serum creatinine levels between the T2DM and con-
trol groups (P > 0.05) (Table 2).
3.2. Genetic analysis
PCR–RFLP results showing the pattern of genotypes for the two
SNPs (rs1527483 and rs1761667) in the CD36 gene have been rep-
resented in Fig. 1a and b.
The allele and genotype frequency distribution and carriage rate
of CD36 gene polymorphisms among 150 controls and 250 patients
Table 2
Sample characteristics for 400 subjects from North Indian population.
Sample characteristics Controls (n = 150) Patients (n = 250) P-value
Age (years) 47.07 ± 6.01 48.39 ± 9.91 0.064
Basal metabolic index, BMI (kg/m2) 23.43 ± 3.83 24.49 ± 4.60 0.701
Waist hip ratio, WHR 0.97 ± 0.06 0.92 ± 0.08 1.000
Fasting plasma glucose, F (mg/dl) 109.69 ± 51.96 166.14 ± 65.76 0.216
Post prandial plasma glucose, PP (mg/dl) 143.69 ± 21.46 266.04 ± 88.45 0.313
Blood pressure systolic, SBP (mmHg) 117.40 ± 5.48 135.22 ± 19.35 0.454
Blood pressure diastolic, DBP (mmHg) 76.80 ± 6.48 84.27 ± 10.77 0.846
Total-cholesterol, TC (mg/dl) 171.65 ± 41.02 225.83 ± 34.83 <0.001
Triglyceride, TGL (mg/dl) 151.87 ± 64.23 112.04 ± 16.88 <0.001
HDL-cholesterol, HDL (mg/dl) 59.07 ± 13.93 43.47 ± 5.26 <0.001
LDL-cholesterol, LDL (mg/dl) 82.21 ± 48.94 158.00 ± 37.04 <0.001
VLDL-cholesterol, VLDL (mg/dl) 30.37 ± 12.85 22.44 ± 3.56 <0.001
Serum creatinine, S. Cret. (mg/dl) 1.08 ± 0.16 1.04 ± 0.09 0.912








bp  GA GG M 2 AA
(b)
Fig. 1. (a) Ethidium bromide stained agarose gel of SNP (C > T) rs1527483 showing
different genotypes; CT: 230, 160, 70 bp; CC: 160, 70; TT: 230; M1: 100 bp ladder
(b) silver stain polyacrylamide gel of SNP (G > A) rs1761667; GA: 190, 138, 52; GG:
138, 52; AA: 190; M2: 50 bp ladder.
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frequencies in control and patient groups were in Hardy–Weinberg
Equilibrium (HWE). The minor allele frequencies (MAF) for both
SNPs in our analysis were P0.1 (Table 3). For C/T polymorphism,
no allelic and genotypic associations were observed in the present
study (P > 0.05). Most subjects were homozygous wild type (CC),
while the TT genotype was rare in the study population (TT geno-
type frequency6 0.01). Allele frequencies of C and T were almost
same in controls and T2DM patients (Table 3).
In case of the G/A promoter polymorphism, although no allelic
association was observed (P = 0.244), the frequency of the GA
genotype was signiﬁcantly higher in T2DM (76.0%) when com-
pared to controls (49.0%, P = <0.001). SNP (G > A) genotypes
showed a highly signiﬁcant association (P < 0.001; OR 3.173; CI
1.098–9.174) with T2DM when compared to controls (Table 3).
Haplotype analysis using logistic regression analysis showed
the possible effect of two genotypes, i.e. double combinations of
SNPs (C > T) and (G > A) on the risk of developing T2DM. Out ofthe nine possible haplotypes, we obtained only six with frequen-
cies ranging from 6% to 37% in this population (Table 4). The fre-
quency of recessive genotypes (AA and TT) was very low in the
population, so their combination with other genotypes was not
considered.
Results showed signiﬁcant association in case of CC/GG and CC/
GA haplotypes (P = <0.05). The risk of CC/AA (+/+, +/) also showed
signiﬁcant association (P = <0.05) while the risk of CT genotype
with GG/GA was highly signiﬁcant (P = <0.05) (Table 4). The risk
of GA and GG without CT genotype was 0.3–2.6 times higher
(P = <0.001), (OR; 0.290 and 2.597; CI 95%; 0.178–0.474 and
1.567–4.303). The risk of diabetes in the combination CT/GA (/
) also showed signiﬁcant association (P = 0.025).
Analysis of the association of haplotypes (double combinations
of genotypes) with biochemical parameters using multivariate lo-
gistic regression brought forth some interesting results. We found
that the subjects without CC/GG genotypes (/) showed signiﬁ-
cant association with TGL and VLDL (P = 0.006). In case of CC/GG
(/+) subjects signiﬁcant association was observed with HDL,
LDL and S. Cret. (P = <0.05). Subjects with CC/GA genotypes (+/+)
showed signiﬁcant association with TC (P = 0.020), LDL
(P = 0.005) and VLDL (P = 0.029) and subjects without GA showed
signiﬁcant association with HDL (P = 0.003) and LDL (P = 0.005).
Subjects with haplotype CC/GA (/+) showed signiﬁcant associa-
tion with TC (P = 0.005) and LDL (P = <0.001) while CC/GA (/)
with TC (P = 0.007), LDL (P = 0.001) and S. Cret. (P = 0.009). Subjects
with CC genotype in combination with AA (+/+) also showed signif-
icant association with TC and LDL (P = 0.003). Subjects having CC
without AA genotype (+/) and CT with GG (+/+) showed signiﬁ-
cant association with HDL (P = 0.034, 0.036). In case of CT/GG (+/
+) subjects signiﬁcant association was observed with LDL
(P = 0.001), but CT/GG (+/) and CT/GA (+/) showed signiﬁcant
association with TGL and VLDL (P = 0.006) and TC, LDL, S. Cret.
(P = 0.007, 0.001, 0.009) respectively. In case of CT/GA (/+) and
(/) genotypes, TC, LDL, VLDL (P = <0.05) and S. Cret.
(P = <0.001) showed signiﬁcant association, respectively (Table 5).
Other haplotypes such as CT/AA, TT/GG etc. were not found in
our population.
4. Discussion
The role of CD36 in lipid metabolism, metabolic syndrome and
T2DM prompted us to investigate its SNP association with T2DM in
our North Indian population. In the present study, we demon-
strated that the GA heterozygous genotype of a promoter polymor-
phism (rs1761667) in the CD36 gene was more prevalent in the
T2DM patients and showed association with diabetes in the North
Indian population. A similar association of a promoter polymor-
phism (rs1527479) in the CD36 gene with insulin resistance and
Table 3
Allele, genotype and carriage rate frequencies (F) of SNPs and their association status with T2DM.
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P = 0.512 P = 0.312 P = 0.483
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v 2 = 1.356 v2 = 35.24 v 2 = 0.887
Promoter A = 0.36
(107)
A = 0.40 (199) AA = 0.11
(17)




P = 0.244 P = < 0.001 P = 0.346
* Number of respective alleles.
** Genotypes.
*** Carriers of alleles in the study population.
Table 4
Distribution of double combinations of the SNPs (C > T) and (G > A) in CD36 gene in









(+&+) 45 (30.0%) 38 (17.59%) 0.011 1.0 (Ref.)
(+&) 75 (50.0%) 142 (65.74%) 0.950 1.032 (0.387–2.753)
(&+) 11 (7.38%) 9 (4.16%) 0.307 1.737 (0.603–5.006)
(&) 19 (12.67%) 27 (1.25%) 0.075 2.314 (0.918–5.831)
CC&GA
(+&+) 56 (37.34%) 136 (62.96%) <0.001 1.0 (Ref.)
(+&) 64 (42.67%) 44 (20.37%) 0.114 1.709 (0.880–3.321)
(&+) 19 (12.66%) 27 (12.5%) 0.307 0.576 (0.200–1.659)
(&) 11 (7.33%) 9 (4.17%) 0.042 0.484 (0.240–0.975)
CC&AA
(+&+) 15 (10%) 5 (2.32%) 0.022 1.0 (Ref.)
(+&) 105 (70.0%) 175 (81.02%) 0.047 164.198 (0.000–
4.9  1011)
(&+) 4 (2.66%) 0 (0.0%) 0.557 682.054 (0.000–
2.0  1012)
(&) 26 (17.34%) 36 (16.67%) 0.546 820.991 (0.000–
2.4  1012)
CT&GG
(+&+) 9 (6.0%) 9 (4.17%) 0.002 1.0 (Ref.)
(+&) 19 (12.67%) 27 (12.50%) 0.604 1.308 (0.475–3.604)
(&+) 51 (34.0%) 39 (18.05%) <0.001 2.597 (1.567–4.303)
(&) 71 (47.34%) 141 (65.28%) 0.092 1.858 (0.905–3.817)
CT&GA
(+&+) 17 (11.34%) 26 (12.03%) <0.001 1.0 (Ref.)
(+&) 11 (7.34%) 9 (4.17%) 0.203 0.641 (0.323–1.272)
(&+) 57 (38.0%) 136 (62.96%) <0.001 0.290 (0.178–0.474)
(&) 65 (43.34%) 45 (20.83%) 0.025 0.343 (0.135–0.872)
182 M. Banerjee et al. / International Journal of Diabetes Mellitus 2 (2010) 179–183T2DM was reported in the Caucasian population at risk for
MetS [17]. However, the allele and genotype frequencies of C/T
(rs1527483) polymorphism in intron 11 were similar in controls
and T2DM patients and did not show any association with T2DM.
This suggested that the regulatory region of the gene is responsible
for the varied expression of the CD36 gene in normal and diseased
conditions since a variant located in the CD36 upstream promoter
determines the binding site for transcription factors [13]. A study
in Italian men has shown that a haplotype of ﬁve SNPs spanning
the CD36 gene was associated with higher free fatty acid and tri-
glyceride levels thereby modulating lipid metabolism and cardio-
vascular risk [13]. It was also suggested that since CD36
modulates the uptake of modiﬁed lipoproteins and is related to
insulin resistance through its contribution to fatty acid metabo-lism, the variants of the CD36 gene may contribute to the patho-
genesis of diabetes in African Americans [14]. A recent study on
the variants of the CD36 gene in Boston and Puerto Rican adults
also revealed its association with metabolic syndrome which can
increase the risk of cardiovascular disease and T2DM [20]. How-
ever, the minor allele frequency of the SNP G > A (rs1761667)
was slightly lower in our population (0.36) compared to 0.46 in
Puerto Ricans [20]. A genetic study in the French diabetic popula-
tion revealed a rare non-sense mutation in the CD36 gene while a
promoter variant178A/C was signiﬁcantly associated with adipo-
nectin levels and represented a putative marker for insulin resis-
tance [15,16]. Another common polymorphism (478 C/T)
associated with CD36 deﬁciency was reported in Japanese patients
with heart disease [21].
Evidence from the literature has shown that CD36 expression in
monocytes is up regulated by oxidized low density lipoprotein and
its level increases in T2DM, hyperglycemia and related atheroscle-
rosis probably through its contribution to disturbed fatty acid
metabolism, [22–24] suggesting a possible connection between
atherosclerosis and insulin resistant states through CD36 [25].
The increased hepatic CD36 protein expression in response to diets
rich in fatty acids and/or to obesity contributes to aberrant liver
fatty acid uptake and subsequent dyslipidemia [26] and the in-
creased foam cell formation in T2DM is caused by decreased mac-
rophage cholesterol efﬂux to HDL. Reports have suggested that it
was associated with abnormal glucose metabolism, and altered
serum lipids and CD36 deﬁciency is a risk factor for MetS [27].
Some studies have reported alterations in FFAs and TGL with a
common haplotype in CD36, especially the SNPs rs1761667 and
rs1049673 have been associated with elevated plasma FFAs in
white men without diabetes [13]. In our study, rs1527483 (C > T)
showed highly signiﬁcant association with lipid levels (P = <
0.001) when considered alone. However, on haplotype analyses
signiﬁcant associations between CD36 SNPs and biochemical
parameters were evident (Table 5). A signiﬁcant difference was ob-
served in total cholesterol (TC) with CC genotype in combination
with GA and AA, but CT without GA was also associated with it.
Subjects without CC/GA genotype (/) were also associated with
TC. TC also showed signiﬁcant association with GA genotype minus
CC and CT. Signiﬁcant differences in TGL levels were also observed
in subjects without CC and GG genotypes but subjects with CT/GG
(+/) were also associated with it. HDL is only associated with CC
genotype except CT/GG (+/+) in combination without GA and AA.
LDL showed its association with CC genotype in combination with
GA, without GA and with AA, but CT genotype showed its associa-
Table 5




TC TGL HDL LDL VLDL S. Cret.
CC&GG +/+ 0.745 0.572 0.536 0.564 0.636 0.348
+/ 0.636 0.720 0.577 0.851 0.955 0.804
/+ 0.402 0.772 0.029 <0.001 0.772 0.023
/ 0.447 0.006 0.889 0.549 0.006 0.462
CC&GA +/+ 0.020 0.258 0.990 0.005 0.029 0.620
+/ 0.240 0.392 0.003 0.045 0.151 0.275
/+ 0.005 0.070 0.611 <0.001 0.070 0.807
/ 0.007 0.382 0.091 0.001 0.382 0.009
CC&AA +/+ 0.003 0.065 0.276 0.003 0.065 0.287
+/ 0.449 0.380 0.034 0.224 0.394 0.953
/ 0.993 0.446 0.943 0.027 0.568 0.867
CT&GG +/+ 0.058 0.701 0.036 0.001 0.701 0.232
+/ 0.447 0.006 0.889 0.549 0.006 0.890
/+ 0.745 0.572 0.536 0.564 0.636 0.348
/ 0.636 0.720 0.577 0.851 0.955 0.804
CT&GA +/+ 0.690 0.700 0.669 0.306 0.715 0.413
+/ 0.007 0.382 0.091 0.001 0.382 0.009
/+ 0.020 0.258 0.111 0.005 0.029 0.620
/ 0.487 0.226 0.704 0.092 0.199 <0.001
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niﬁcant association with VLDL only in case of CC/GG (/), CC/
GA (+/+), CT/GG (+/) and CT/GA (/+). In case of S. Cret. subjects
without CC and GA, subjects with CT and without GA, subjects
without CT and GA, subjects with GG and GG without CC showed
a highly signiﬁcant association. The association of these haplotypes
with biochemical parameters indicates that somehow they are
responsible for the manifestation of the disease, for example,
although CT genotype was not prevalent among the North Indian
diabetic patients but in combination with the high-risk genotype
GA showed signiﬁcant associations with TC, LDL, VLDL etc. suggest-
ing that the selected SNPs have a synergistic effect on T2DM. In
addition, the presence of the minor allele A* of rs1761667 in the
-31118 promoter region of the CD36 gene seemed to contribute
greatly in elevating the risk of developing this disorder.
5. Conclusions
In conclusion, this is perhaps the ﬁrst study to examine the
association of CD36 polymorphisms in North Indian adults, a
high-risk urban population. Considering that CD36 plays a crucial
role in T2DM, we showed that the 5’ promoter SNP rs1761667
has a signiﬁcant association with T2DM patients in this population.
Our results suggest that individuals having a ‘GA’ genotype might
be susceptible to T2DM and may be at risk of developing related
complications. Moreover, it has provided a lead for future studies
to examine the role of other CD36 variants in the development of
T2DM in India and other ethnic populations.
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